Skip to main content

Advertisement

Table 4 2006 Versus 2015 direct ophthalmic medical costs and patient value gain versus ranibizumab therapy for first two years

From: The comparative effectiveness and cost-effectiveness of ranibizumab for neovascular macular degeneration revisited

Cost 2006 2015
Physician $6167 (11.7%) $2611 (5.6%)
Ranibizumab $44,812 (85.2%) $42,665 (91.9%)
Diagnostic tests $1230 (2.3%) $1174 (2.5%)
Post-operative antibiotics $414 (0.8%) $0 (0.0%)
Total $52,652 (100%) $46,450 (100%)
Adjusted with medical CPI to 2015 US $ $70,161 $46,450
Decrease in real dollars from 2006 to 2015 NA −33.8%
Patient value (quality-of-life) gain 2006 2015
First-eye model 6.4% 9.8%
Second-eye model 15.8% 22.8%
Combined-eye model 10.4% 16.3%
  1. Parentheses indicate percent of total direct ophthalmic medical costs. NA not applicable. Note that patient value gain = quality-of-life gain